SCHEDULE: Viking Global Discloses 5.9% Stake in Trevi Therapeutics

Viking Global Investors LP and its affiliates reported a beneficial ownership of 5.9% in Trevi Therapeutics, Inc., including common stock and pre-funded warrants.

Summary

• Viking Global Investors LP and its affiliated entities, along with O. Andreas Halvorsen, David C. Ott, and Rose S. Shabet, collectively reported beneficial ownership of 7,505,694 shares of Trevi Therapeutics, Inc. common stock.
• This aggregate ownership represents 5.9% of Trevi Therapeutics' outstanding common stock.
• The reported shares include 1,543,000 shares directly owned (1,033,810 by Viking Global Opportunities Illiquid Investments Sub-Master LP and 509,190 by Viking Global Opportunities Drawdown (Aggregator) LP) and 5,962,694 shares purchasable through pre-funded warrants with an exercise price of $0.001 per share.
• The beneficial ownership is shared among the various reporting entities and individuals, with no sole voting or dispositive power.
• The percentages are calculated based on 121,775,753 shares of common stock outstanding as of June 30, 2025, as reported in Trevi Therapeutics' Form 10-Q filed on August 7, 2025, plus the 5,962,694 shares purchasable via warrants.

Sentiment

Score: 6

Explanation: The filing is a standard beneficial ownership disclosure, which is generally neutral. However, the disclosure of a significant stake by a prominent investment firm like Viking Global can be perceived positively by the market, suggesting institutional confidence. The inclusion of warrants also implies a past or potential future capital event.

Positives

• A significant institutional investor, Viking Global, has taken a substantial stake in Trevi Therapeutics, potentially signaling confidence in the company's future prospects.
• The investment includes pre-funded warrants, indicating a long-term commitment and providing potential future capital to the company upon exercise.

Future Outlook

NA

Industry Context

This filing indicates a significant investment by a major global investment firm, Viking Global, into Trevi Therapeutics, a company likely operating in the biotechnology or pharmaceutical sector given its name. Such an investment suggests a belief in the long-term potential of Trevi's pipeline or market position within the broader healthcare industry.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may increase investor confidence and potentially influence stock price positively.
• Company Management: Awareness of a large, active institutional investor on the shareholder register may influence strategic decisions or communication.

Next Steps

• The reporting persons will continue to prepare jointly and file timely all required Forms 3, 4, or 5 or Schedules 13D or 13G, and any amendments thereto, as required by the Securities Exchange Act of 1934.

Key Dates

Recommendation

This filing is a disclosure of beneficial ownership by a major institutional investor, Viking Global. While the acquisition of a significant stake (5.9%) by such a firm can be seen as a positive signal of confidence in Trevi Therapeutics, the filing itself does not provide sufficient financial or operational details to warrant a 'buy' or 'sell' recommendation. It primarily serves as an informational update on the shareholder base. Investors should 'hold' and await further operational or financial updates from Trevi Therapeutics to make a more informed decision, while noting the positive signal from Viking Global's investment.

Keywords

Trevi Therapeutics, Viking Global Investors, SEC filing, Schedule 13G, beneficial ownership, common stock, warrants, institutional investment, TRVI, healthcare, biotechnology